Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Impact of chronic fibrosing interstitial lung disease on healthcare use: association between fvc decline and inpatient hospitalization

View through CrossRef
Abstract Background Many types of interstitial lung diseases (ILDs) may transition to progressive chronic-fibrosing ILDs with rapid lung function decline and a negative survival prognosis. In real-world clinical settings, forced vital capacity (FVC) measures demonstrating progressive decline may be linked to negative outcomes, including increased risks of costly healthcare resource utilization (HRU). Thus, we assessed the relationship between rate of decline in lung function and an increase in HRU, specifically inpatient hospitalization, among patients with chronic fibrosing ILD. Methods This study utilized electronic health records from 01-Oct-2015 to 31-Oct-2019. Eligible patients (≥ 18 years old) had ≥ 2 fibrosing ILD diagnosis codes, clinical activity for ≥ 15 months, and ≥ 2 FVC tests occurring 6 months apart. Patients with missing demographic data, IPF, or use of nintedanib or pirfenidone were excluded. Two groups were defined by relative change in percent of predicted FVC (FVC% pred) from baseline to 6 months: significant decline (≥ 10%) vs. marginal decline/stable FVC (decrease < 10% or increase). The primary outcome was defined as the occurrence of an inpatient hospitalization 6 months after the first FVC value. Descriptive and multivariable analysis was conducted to examine the impact of FVC decline on occurrence of inpatient hospitalization. Results The sample included 566 patients: 13% (n = 75) with significant decline and 87% (n = 491) with marginal decline/stable FVC; their mean age (SD) was 65 (13.7) years and 56% were female. Autoimmune diagnoses were observed among 40% of patients with significant decline, and 27% with marginal decline/stable FVC. The significant decline group had better lung function at baseline than the marginal/stable group. For patients with FVC% <80% at baseline, reduction of FVC% ≥10% was associated with significantly increased odds of an inpatient hospitalization (odds ratio [OR] 2.85; confidence interval [CI] 1.17, 6.94 [p = 0.021]). Conclusion Decline in FVC% ≥10% was associated with increased odds of inpatient hospitalization among patients with reduced lung function at baseline. These findings support the importance of preserving lung function among patients with fibrosing ILD.
Title: Impact of chronic fibrosing interstitial lung disease on healthcare use: association between fvc decline and inpatient hospitalization
Description:
Abstract Background Many types of interstitial lung diseases (ILDs) may transition to progressive chronic-fibrosing ILDs with rapid lung function decline and a negative survival prognosis.
In real-world clinical settings, forced vital capacity (FVC) measures demonstrating progressive decline may be linked to negative outcomes, including increased risks of costly healthcare resource utilization (HRU).
Thus, we assessed the relationship between rate of decline in lung function and an increase in HRU, specifically inpatient hospitalization, among patients with chronic fibrosing ILD.
Methods This study utilized electronic health records from 01-Oct-2015 to 31-Oct-2019.
Eligible patients (≥ 18 years old) had ≥ 2 fibrosing ILD diagnosis codes, clinical activity for ≥ 15 months, and ≥ 2 FVC tests occurring 6 months apart.
Patients with missing demographic data, IPF, or use of nintedanib or pirfenidone were excluded.
Two groups were defined by relative change in percent of predicted FVC (FVC% pred) from baseline to 6 months: significant decline (≥ 10%) vs.
marginal decline/stable FVC (decrease < 10% or increase).
The primary outcome was defined as the occurrence of an inpatient hospitalization 6 months after the first FVC value.
Descriptive and multivariable analysis was conducted to examine the impact of FVC decline on occurrence of inpatient hospitalization.
Results The sample included 566 patients: 13% (n = 75) with significant decline and 87% (n = 491) with marginal decline/stable FVC; their mean age (SD) was 65 (13.
7) years and 56% were female.
Autoimmune diagnoses were observed among 40% of patients with significant decline, and 27% with marginal decline/stable FVC.
The significant decline group had better lung function at baseline than the marginal/stable group.
For patients with FVC% <80% at baseline, reduction of FVC% ≥10% was associated with significantly increased odds of an inpatient hospitalization (odds ratio [OR] 2.
85; confidence interval [CI] 1.
17, 6.
94 [p = 0.
021]).
Conclusion Decline in FVC% ≥10% was associated with increased odds of inpatient hospitalization among patients with reduced lung function at baseline.
These findings support the importance of preserving lung function among patients with fibrosing ILD.

Related Results

Assessing variance in inpatient hospitalization rates for three major chronic conditions
Assessing variance in inpatient hospitalization rates for three major chronic conditions
Introduction: A chronic condition is broadly defined as a health condition lasting one or more years that requires relatively consistent medical attention and/or imposes limitation...
Perceptions of Telemedicine and Rural Healthcare Access in a Developing Country: A Case Study of Bayelsa State, Nigeria
Perceptions of Telemedicine and Rural Healthcare Access in a Developing Country: A Case Study of Bayelsa State, Nigeria
Abstract Introduction Telemedicine is the remote delivery of healthcare services using information and communication technologies and has gained global recognition as a solution to...
Understanding cystic lung lesions in smokers with interstitial lung disease: radiologic–pathological correlation
Understanding cystic lung lesions in smokers with interstitial lung disease: radiologic–pathological correlation
Abstract Due to destructive, fibrotic, and remodeling mechanisms, we can find a varied constellation of aerated and cystic lung lesions in smoker patients with intersti...
The Impact of IL28B Gene Polymorphisms on Drug Responses
The Impact of IL28B Gene Polymorphisms on Drug Responses
To achieve high therapeutic efficacy in the patient, information on pharmacokinetics, pharmacodynamics, and pharmacogenetics is required. With the development of science and techno...
Correlation between spirometric findings and 6-min walk test in patients with chronic obstructive pulmonary disease
Correlation between spirometric findings and 6-min walk test in patients with chronic obstructive pulmonary disease
Background: Chronic obstructive pulmonary disease (COPD) is characterized by permanent respiratory symptoms and limitation of airflow which is due to airway and/or alveolar abnorma...
Blunt Chest Trauma and Chylothorax: A Systematic Review
Blunt Chest Trauma and Chylothorax: A Systematic Review
Abstract Introduction: Although traumatic chylothorax is predominantly associated with penetrating injuries, instances following blunt trauma, as a rare and challenging condition, ...
Impact of Cigarettes Smoking on Undergraduates’ Lung Health and Functional Performance: Observational Cross-Sectional Study
Impact of Cigarettes Smoking on Undergraduates’ Lung Health and Functional Performance: Observational Cross-Sectional Study
Background: Cigarettes Smoking is a major social and global health problem. Cigarette smoking continues to be a major contributor to deteriorated health status across d...
Evaluation of lung adverse events with trastuzumab using the Japanese pharmacovigilance database
Evaluation of lung adverse events with trastuzumab using the Japanese pharmacovigilance database
Abstract The present study aimed to determine the risk of trastuzumab-induced lung toxicity, time to onset, and post hoc outcomes using the Japanese Adverse Drug Event Repo...

Back to Top